Previous Prostate Research Projects

Since 2009 the Spotlight Prostate Cancer Appeal has raised £7,700,000. This is being used to fund research into prostate cancer. The projects which have been funded to date are:

  • University of Sheffield. Commenced 1 October 1999. Why do prostate cancers spread to the bones and cause new bone growth? 3 Year Funding: £120,000
  • University of Bristol. Commenced 1 October 1999. How do growth factors and male hormones affect the growth and survival of prostate cancer cells? 3 Year funding: £94,000
  • University of Oxford. Commenced 1 October 1999. Analysing exactly which genetic changes lead to cancer of the prostate. 3 Year funding: £121,000
  • Imperial College of Science, Technology & Medicine. Commenced 1 October 2000. Investigating the mechanism of hormone therapy for prostate cancer. 3 Year funding: £142,000
  • Erasmus University Rotterdam. Commenced 1 October 2000. Identifying proteins involved in prostate cancer cell suicide. 3 Year funding: £126,000
  • Imperial College of Science, Technology & Medicine. Commenced 1 October 2000. Identifying the growth factors of prostate cells. 3 Year funding: £136,000
  • University of Bath. Commenced 1 October 2001. Towards a polymeric prodrug system for selective delivery of cytotoxins to prostate tumours. 3 Year funding: £58,720
  • University of Newcastle. Commenced 1 October 2001. Modulation of androgen receptor-mediated cellular signalling in human prostate cancer by the coactivator protein TIP60. 3 Year funding: £114,538
  • University of Edinburgh. Commenced 1 April 2002. Role of CYP7B, a novel cytochrome P450 enzyme in prostate cancer progression. 3 Year funding: £139,390
  • Imperial College of Science, Technology & Medicine. Commenced 1 October 2002. Functional characterisation of novel androgen receptor - interacting proteins. 3 Year funding: £75,850

  • University of Cambridge. Commenced April 2004. Dog odour discrimination and human health. 1 year funding £48,210

  • University of Leuven. Commenced April 2004. Structure-function analysis of the amino-terminal domain of the androgen receptor and its co-activators. 3 year funding: £102,204

  • University of Helsinki. Commenced April 2004. Androgen receptor-dependent transcriptional regulation in prostate cells:  coregulator dynamics and the role of ubiquitin and SUMO modifications. 3 year funding:  £129,108

  • University of Dundee. Commenced October 2004. PPARo as a drug target in prostate cancer. 3 year funding:  £114,983

  • Newcastle University. Commenced October 2004. Regulation of HDAC1; a component of the androgen receptor transcriptosome and potential therapeutic target in prostate cancer. 3 year funding:  £129,660

  • Paterson Institute for Cancer Research. Commenced October 2004. Lipidomic Analysis of Metastatic Prostate Cancer. 3 year funding: £123,944

  • Glasgow Royal Infirmary. Commenced April 2005. The role of the P13K/Akt pathway in the development of androgen independent prostate cancer. 2 year funding: £51,727

  • Queens University Belfast. Commenced October 2005. Relationship and impact of constitutive IL-8 signalling on Hsp90- and proteasome-targeted therapies in androgen independent prostate cancer. 3.5 year funding: £151,094

  • Imperial College London. Commenced October 2005. Role of prohibitin in androgen regulation of prostate cancer growth. 3 year funding: £105,384

  • University of Glasgow. Commenced October 2005. The role of PI3K/Akt pathway in the development of androgen independant prostate cancer. 2 year funding: £58,691

  • IGBMC. Commenced October 2005. Evaluation of the role of the Net transcription factor in prostate cancer progression and angiogenesis. 3 year funding: £141,900

  • ACS Inserm Paris V Sainte Anne. Commenced October 2005. Prolactin antagonista as new inhibitors of prostate tumor growth. 3 year funding: £137,511

  • University of Newcastle upon Tyne. Commenced October 2005. The design, synthesis and evaluation of small-molecule inhibitors of Tip60 histone acetyltransferase. 3.5 year funding: £126,976

  • University of Edinburgh. Commenced October 2006. The putative role of proteolysis-inducing factor in prostate cancer. 2 year funding: £102,913

  • University of Newcastle upon Tyne. Commenced October 2006. Identification and Characterisation of Pre-mRNA Splicing Changes Associated with the Switch between Hormone Insensitive and Sensitive Prostate Cancer. 3 year funding: £127,012

  • University of Parma. Commenced October 2006. A new animal model for prostate cancer:  addressing the role of clusterin in tumor progression. 3 year funding: £98,018

  • University of Newcastle upon Tyne. Commenced October 2007. The Role of Histone Methyltransferase and Demethylase Enzymes in Androgen Receptor Regulation and Prostate Cancer. 3 year funding: £163,001

  • Queens University Belfast. Commenced October 2007. Elucidating the importance of cancer cell-derived interleukin-8 in potentiating the bony metastasis of prostate cancer. 3 year funding: £159,494

  • Forschungszentrum Karlsruhe. Commenced October 2007. Inhibition of action of Bag-1L as a measure of preventing prostate cancer development and metastasis. 3 year funding: £155,509

  • University of Bath. Commenced April 2008. Refinement of a new prodrug clip for prostate-selective drug delivery. 2 year funding: £105,811

  • Imperial College London. Commences October 2008. Cooperation between pericellular and intracellular collagen degradation pathways during prostate cancer invasion. 3 year funding: £153,745

  • Fondazione Santa Lucia. Commences October 2008. Role of the RNA-binding protein Sam68 in prostate cancer cell proliferation and survival. 3 year funding: £86,358

  • University of Glasgow. Commences October 2008. Is phosphorylation of the androgen receptor of clinical significance in the development and progression of prostate cancer? 2 year funding: £68,415
  • University of Cambridge, England. Commences April 2008. Investigating the genes involved in breast and prostate cancers. 3 year funding: £210,206.
  • Imperial College, London. Predicting whether prostate cancer will spread. 3 year funding: £186,298.
  • University of Rome. Commences April 2008. Prostate cancer and the Sam68 gene; what is the link? 3 year funding: £86,358
 

Content managed by CC Technology